FDA Broadens Caplyta Approval to Include Major Depression

(MedPage Today) — The FDA approved lumateperone (Caplyta) as an adjunctive therapy with antidepressants for the treatment of major depressive disorder in adults, Johnson & Johnson announced.
Lumateperone was previously approved as an adjunctive…